Zymeworks Inc. (ZYME) stock
ZYMENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30141% above fair value
$26.47−2.60 (-8.94%)
Close on Nov 12, 2026Market cap $1.88BP/E 50.9Yield –
Zymeworks enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Zymeworks's enterprise value was $1.90B on Nov 11, 2026, against $1.94B a year earlier. Over the last 5 years it ranged from -$5.45M to $2.01B, with a median of $583.73M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $1.90B | -0.9% |
| 2025 | Dec 31, 2025 | $1.91B | +113.5% |
| 2024 | Dec 31, 2024 | $896.37M | +118.5% |
| 2023 | Dec 29, 2023 | $410.31M | +28.8% |
| 2022 | Dec 30, 2022 | $318.68M | -45.4% |
| 2021 | Dec 31, 2021 | $583.73M | – |
See a number that looks wrong?